Vitamin D Testing Now Offered In-house
Gamma Healthcare is pleased to announce the addition of total
Vitamin D testing to its in-house test menu.
In 2009 the Archives of Internal Medicine reported that
77% of adults in the United States suffered from Vitamin D
insufficiency resulting from limited exposure to the sun and diets
deficient in Vitamin D. Studies indicate a correlation
between deficient Vitamin D levels and health conditions.
These factors have produced a dramatic increase in requests for
Vitamin D testing. To meet this demand and improve service to
both our client and our patients, on November 7, 2011, Gamma
Healthcare began offering total Vitamin D testing in-house.
This service will decrease turn-around-time from 72 hours to less
than 24 hours in most cases.
Two types of Vitamin D have been identified: Vitamin
D2 (ergocalciferol) from plants and Vitamin
D3 (cholecalciferol) from sunlight and fatty fish such
as herring and mackerel. Measurement of total Vitamin D
(D2 and D3) is necessary for aiding correct
interpretations of a patient's status. Not all Vitamin D
assays available on the market measure total Vitamin D. Gamma
Healthcare employs the ADVIA Centaur XP Vitamin D Total Assay by
Siemens, which does measure total Vitamin D aiding correct patient
The emerging evidence associating Vitamin D deficiency with
serious health conditions is making it critical that the general
public know how to maintain and monitor adequate Vitamin D
levels. Gamma Healthcare in conjunction with Siemens
Healthcare Diagnostics - both leaders in clinical diagnostics - are
playing a role in helping people achieve good health by employing
performance-driven solutions, which assist in diagnosing, treating
and monitoring disease. Following these four tips will help
in maintaining healthy levels of Vitamin D:
Contact the Gamma Healthcare Customer Service Center for further
information regarding test method, specimen requirements or
July 20, 2011
Re: Clostridium difficile Testing
Gamma HealthCare, Inc. will be offering a new molecular
diagnostic test for Clostridium difficile starting August
15, 2011. Rapid identification of toxigenic
Clostridium difficile in the stool samples of patients
showing signs and symptoms of C. difficile infection can
be critical to patient care and management.
We will be offering the Meridian Bioscience, Inc.,
illumigene™ C. difficile Assay. This is a
qualitative, in vitro diagnostic, molecular amplification
test that detects the pathogenicity locus by targeting the tcdA
target region which is found in all A+B+ and A-B+ toxinotypes.
By providing this test we can offer you:
illumigene™ C. difficile Assay utilizes Loop
Mediated Isothermal Amplification (LAMP) to detect toxin gene
sequences associated with toxin producing C.
difficile. The assay has been evaluated to provide
a sensitivity and specificity of 95.2% and 95.3% respectively when
compared directly to the gold standard of toxigenic culture.
Additional literature is available from the laboratory.
Please contact us if you have any questions.
April 21st, 2011
To increase the quality of occult blood testing for our patients
we have updated our testing option for Occult Blood, Fecal.
The new test is Fecal Occult Blood-Immunochem; test code 10317.
This immunochemical test provides several advantages over the
Guaiac method including greater specificity and
sensitivity for human hemoglobin, ease of collection,
reduction in the number of samples needed (only one
required), and no dietary or medicine restrictions.
Due to significant improvement over the current guaiac method,
as of May 1st, 2011 we will no longer offer Occult
Blood, Fecal by guaiac methodology; test code 201. Any specimen
received on a card or sterile container will be rejected. All
specimens for occult blood testing must be collected in the
specific collection container provided and according to collection
instructions for the updated test FOB-I; 10317. The
container will be forwarded to our main laboratory where the result
will be determined by our OC-Auto 80 analyzer, removing
subjectivity from the analysis.
SAMPLE CONTAINERS ARE PROVIDED BY GAMMA HEALTHCARE.
USING SAMPLING PROBE SCRAPE THE SURFACE OF THE FECAL SAMPLE. COVER
THE GROOVED PORTION OF THE PROBE COMPLETELY. CLOSE THE
SAMPLING BOTTLE BY INSERTING THE SAMPLING PROBE AND SNAP CAP
TIGHTLY. DO NOT REOPEN. ONLY ONE SAMPLE DESIRED; SERIES
OF THREE NOT NECESSARY.
TRANSPORT: COLLECTION VIAL TO GAMMA HEALTHCARE.
REMARKS: STOOL SHOULD BE PUT INTO COLLECTION DEVICE
IMMEDIATELY AFTER COLLECTION.
STABILITY: STOOL WITHIN THE COLLECTION DEVICE:
AMBIENT: 15 DAYS; REFRIGERATED: 30 DAYS.
If you are interested in purchasing FOB guaiac kits for your own
use they are available from supply at $32.25 per 50 cards with
developer or $64.50 per 100 cards with developer.
Click the link below to read the article in the Andalusia Star
Newspaper on Gamma's new lab coming soon to Andalusia, AL!
December 15, 2010
Jerry Murphy, Chairman and Owner of Gamma HealthCare, Inc.,
would like to announce the construction of a new state of the art
Clinical Laboratory located inside the Physicians Park Building in
This new facility will allow Gamma HealthCare, Inc. the ability
to expand its clinical laboratory services to the state of Alabama
and the entire Southeast. "This project will provide the city
of Andalusia and the surrounding areas with a choice for their
laboratory testing needs," says Mr. Murphy. According to Mr.
Murphy Gamma HealthCare, Inc. has been looking for the right
opportunity to expand in this region. He continued by saying,
"Andalusia will be a vital part of our growth strategy in the
Southeast. We will be able to service Southern MS, Alabama,
Western Georgia and North West Florida from this location."
Olin Harden, Marc McIntyre and Dr. Tim Day of HDM Group
LLC are building the new Physicians Park located on South Three
Notch Street in Andalusia, AL. "We are excited to have Gamma
HealthCare, Inc. as a laboratory provider for our community.
They will be able to provide high quality healthcare services to
the local physicians and the citizens of the communities we serve,"
said Mr. Harden
Gamma HealthCare, Inc. is headquartered in Poplar Bluff,
MO. Gamma employs approximately 400 employees throughout 11
different states. They provide Clinical Laboratory services
to individuals, Physicians and Long Term Care Facilities throughout
the Midwest and Southeast. Gamma also provides Mobile
Radiology Imaging and Medical Waste Disposal services to the areas
You may wish to follow the progress of this construction project
Completion of this project is scheduled for late summer 2011.
Urodynamics is the new service that Gamma now provides.
Only Gamma HealthCare offers Long Term Care facilities Urodynamics
services with the Midwest. What is Urodynamics? It
involves a collection of studies that help to evaluate the lower
urinary tract including the bladder and urethra. If the
patient demonstrates certain symptoms such as urinary frequency,
urgency, incontinence then they may be a candidate for our
Up to 50% of nursing time is spent managing urinary incontinence
and its conscequences taking time away from other duties.
With our program the nursing staff is able to focus more on the
residents' primary care needs.
The leading provider of onsite technology for the treatment and
disposal of medical waste and the destruction of confidential
documents and related media, today announced it has signed a
distributor agreement with Gamma Healthcare, Inc./Danner Medical
Waste Management Services, a premier provider of medical diagnostic
services that include laboratory, portable digital radiology,
urodynamics, along with medical waste transportation and disposal
services. This agreement will enable Gamma Healthcare to expand its
service offerings and to provide integrated onsite medical waste
disposal and onsite document destruction technology and services as
complementary services to its existing medical waste transportation
line of business. The structure of the agreement enables both
companies to collaborate on and target their integrated technology
and services to the more than 700 large quantity medical waste
generators and the nearly 2,500 medium quantity medical waste
generators in the seven-state region.
"We are pleased and excited to partner with a first-class
organization such as Gamma Healthcare, including its Danner Medical
Waste division," commented David Laky, President and CEO, MedClean
Technologies, Inc. "This partnership provides considerable
expansion to our distributor network, which now covers 13 states.
Gamma currently has 11 office locations with sales representatives
servicing its region who already possess significant established
relationships with ideal target customers across the Midwest. Our
job is to provide the Gamma team with the technology and services
required to support rapid expansion of its medical waste disposal
line of business."
Mr. Laky continued, "This opportunity represents a significant
milestone for MedClean Technologies as well. Our goals and targets
communicated earlier in the year included building a distributor
network consisting of at least five new distributors as well as
other strategic partners. Gamma represents our fourth and largest
distributor, with all four signed prior to the mid-year mark. Our
distributors and partners combine to span two countries, over 5,000
targets, the VA Health System, and over one third of North America.
We expect the combination of Gamma's regional excellence and
MedClean's technology and services to result in new business
yielding up to $2 million in revenue for each company during the
first year of the partnership, as we believe Gamma has the
potential to achieve significant revenue and rapid expansion in the
"The MedClean product line is a natural addition to our current
business model, as well as for our plans to expand our medical
waste hauling and confidential document destruction and recycling
business," added Jerrod Murphy, President and COO of Gamma
Healthcare. "We are now in the position to establish processing
facilities throughout our region utilizing various configurations
of the MedClean Series of equipment. This flexibility will enable
us to further evolve to a full service provider to meet the wide
array of our clients' needs. We will also be able to expand our
target medical waste customer base through servicing customers no
matter how small or large their volume of medical waste as well as
possessing the ability to meet their waste treatment
"We are excited and looking forward to our relationship with
MedClean Technologies, Inc.," commented Jerry Murphy, Chairman and
CEO of Gamma Healthcare, Inc. This partnership will give us the
ability to expand the services that we currently offer and allow us
to reach new business relationships within our current market
BETHEL, Conn., July 22, 2010 /PRNewswire via COMTEX/ -- MedClean
Technologies /quotes/comstock/11k!mcln (MCLN 0.01, +0.00, +20.17%)